<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200601047630N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-18</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of progesterone in preventing LH surge in IVF cycles</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of progesterone effect in preventing LH surge and quality of oocytes and embryos in IVF cycles with patients undergoing antagonist cycle in Shariati Hospital during 97-98</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48593</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, all patients who meet the inclusion criteria are entered into an Excel column, and then using the Rand option in this software, in the opposite column, each patient is randomly assigned the number 1 or 2. No. 1: Intervention group and No. 2: control group.</study_design>
      <phase>1-2</phase>
      <hc_freetext>Infertility.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: On day 2-3 of the gonadotropin cycle, including FSH with or without HMG, with medroxyprogesterone 5 mg daily, two doses are given. Vaginal ultrasounds were performed on days 9 to 10, and if 18 to 20 mm follicles were found, HCG was injected for ovulation. Then, 36 hours later, the puncture was performed. If the follicle was less than 18 mm, the Continuation of gonadotropin is done with an additional dose and medroxyprogesterone and ultrasound on the 12th day, and again if on the ultrasound of the 12th day the follicle was 18 to 20 mm, HCG is injected. If the follicle is less than 18 mm, gonadotropin and medroxyprogesterone are continued and then ultrasound is performed on day 14 and a decision is made accordingly. This process continues until day 25 of the cycle and until the follicle responds to treatment, until the day of HCG injection. And medroxyprogesterone is given and medroxyprogesterone is discontinued on the day of HCG injection. Intervention 2: Control group: In the control group, 2 to 3 cycles of gonadotropin, including FSH with or without HMG, are given on day 3, then one week later, vaginal ultrasound is performed. If the follicle is between 18 and 20 mm, HCG is injected for ovulation and then a puncture for IVF is performed 36 hours later. If the follicle is larger than 14 mm, asteroid (gonadotropin antagonist) is given with gonadotropin, and ultrasound is done again on the 12th day. If the follicle is less than 14 mm, the gonadotropin is continued with a double dose and the ultrasound is repeated on the 12th day. On day 12 ultrasound, if an 18 to 20 mm follicle is found, HCG is injected for ovulation and then a puncture is performed 36 hours later.If a 14 mm follicle is found on the ultrasound on day 12, the steroid is started, along with continued gonadotropin, and on day 14 sonography will be done again. If the follicle was less than 14 mm on day 12, the gonadotropin will be continued with an overdose, and on day 14, an ultrasound will be performed, and a decision will be made based on the sonography on day 14. This process can continue until the 25th day of the cycle, ie until the follicle responds to the drug. And patients are excluded from the study when they have a follicle less than 8 mm at the beginning, in fact, 14 mm follicle is the time of onset of steroid and follicle 18 to 20 mm is the time of onset of HCG and continues until the day of HCG gonadotropin and steroid injection.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only a part of the data, such as information about the main consequence or the like, can be shared

When:
Start the access period 6 months after printing the results

To whom:
Data will only be available to researchers working at academic and scientific institutions

Conditions:
For research only

Where to obtain:
the email of Dr. Pouri

How to obtain:
Apply via email and specify the purpose of using the data

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara Pouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalal highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 1000</telephone>
        <email>Sarapouri65@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ayda Najafian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalal highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 1000</telephone>
        <email>anajafian@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The age between 18 and 35 years ,,
a normal sperm test
a normal body mass index (18-30 kg / m2)
the presence of both ovaries and the opening of the tubes</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Tubal factor
severe endometriosis
hypothalamic amenorrhea
oligoasthenospermia (abnormal sperm count and shape)
severe uterine anomalies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: On day 2-3 of the gonadotropin cycle, including FSH with or without HMG, with medroxyprogesterone 5 mg daily, two doses are given. Vaginal ultrasounds were performed on days 9 to 10, and if 18 to 20 mm follicles were found, HCG was injected for ovulation. Then, 36 hours later, the puncture was performed. If the follicle was less than 18 mm, the Continuation of gonadotropin is done with an additional dose and medroxyprogesterone and ultrasound on the 12th day, and again if on the ultrasound of the 12th day the follicle was 18 to 20 mm, HCG is injected. If the follicle is less than 18 mm, gonadotropin and medroxyprogesterone are continued and then ultrasound is performed on day 14 and a decision is made accordingly. This process continues until day 25 of the cycle and until the follicle responds to treatment, until the day of HCG injection. And medroxyprogesterone is given and medroxyprogesterone is discontinued on the day of HCG injection.</i_keyword>
      <i_keyword>Control group: In the control group, 2 to 3 cycles of gonadotropin, including FSH with or without HMG, are given on day 3, then one week later, vaginal ultrasound is performed. If the follicle is between 18 and 20 mm, HCG is injected for ovulation and then a puncture for IVF is performed 36 hours later. If the follicle is larger than 14 mm, asteroid (gonadotropin antagonist) is given with gonadotropin, and ultrasound is done again on the 12th day. If the follicle is less than 14 mm, the gonadotropin is continued with a double dose and the ultrasound is repeated on the 12th day. On day 12 ultrasound, if an 18 to 20 mm follicle is found, HCG is injected for ovulation and then a puncture is performed 36 hours later.If a 14 mm follicle is found on the ultrasound on day 12, the steroid is started, along with continued gonadotropin, and on day 14 sonography will be done again. If the follicle was less than 14 mm on day 12, the gonadotropin will be continued with an overdose, and on day 14, an ultrasound will be performed, and a decision will be made based on the sonography on day 14. This process can continue until the 25th day of the cycle, ie until the follicle responds to the drug. And patients are excluded from the study when they have a follicle less than 8 mm at the beginning, in fact, 14 mm follicle is the time of onset of steroid and follicle 18 to 20 mm is the time of onset of HCG and continues until the day of HCG gonadotropin and steroid injection.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>LH surge. Timepoint: End of pregnancy. Method of measurement: blood tests.</prim_outcome>
      <prim_outcome>Quality of oocyte. Timepoint: End of pregnancy. Method of measurement: Blood tests.</prim_outcome>
      <prim_outcome>Quality of embryo. Timepoint: End of pregnancy. Method of measurement: Blood tests.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Clinical pregnancy. Timepoint: Day 25 of cycle. Method of measurement: Blood analysis.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-04</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Qods st. TUMS Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
